Extra: Sales figures before buyout.
Dermira generated 32,646 prescriptions for QBREXZA as reported by Symphony PHAST monthly data for the third quarter of 2019, an increase of over 14 percent compared to the second quarter of 2019. Grew physician adoption to more than 15,200 unique prescribers writing for QBREXZA during the first 12 months of the launch.
Drawing comparisons between Dermira and Botanix is interesting. The Reddit forum loves QBREXZA with several mentions a day about the treatment. I see them as our major direct competitor we can learn from.
BOT - Anything but charting, page-9413
-
- There are more pages in this discussion • 1,463 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $671.1M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 37.0¢ | $1.949M | 5.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 163455 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 33207 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |